Cancer

K2 Laboratory Obtains NDC Codes for Two Investigational Drugs

K2 Laboratory recently announced that its two investigational drugs, Brain Rehabilitation oral solution and Telomerase Inhibitor oral solution, have successfully…

1 year ago

Tufts Medical Center Becomes First Hospital in Massachusetts to Adopt MOLLI Surgical’s Breast Cancer Technology

MOLLI® 2 System offers breast cancer patients unmatched surgical precision and enhanced comfort BOSTON, July 18, 2024 /PRNewswire/ -- MOLLI Surgical…

1 year ago

Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer’s biosimilar to Humira®

First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18,…

1 year ago

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning

Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation…

1 year ago

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of…

1 year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared ablation technology from RF Innovations, Inc.…

1 year ago

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company…

1 year ago

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar…

1 year ago

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and…

1 year ago